# First Time in Human Study of Long Acting VH4524184 Formulations

> **NCT06310551** · PHASE1 · RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 268 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Oral VH4524184
- **DRUG:** VH4524184 Formulation A SC
- **DRUG:** Placebo Formulation A SC
- **DRUG:** rHuPH20
- **DRUG:** VH4524184 Formulation B SC
- **DRUG:** Placebo Formulation B SC
- **DRUG:** VH4524184 Formulation A IM
- **DRUG:** Placebo Formulation A IM
- **DRUG:** VH4524184 Formulation B IM
- **DRUG:** Placebo Formulation B IM

## Key facts

- **NCT ID:** NCT06310551
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-21
- **Primary completion:** 2028-01-21
- **Final completion:** 2028-01-21
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06310551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06310551, "First Time in Human Study of Long Acting VH4524184 Formulations". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06310551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*